Veru
Update in progressVERU (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Veru Inc. is a late-stage biopharmaceutical company focused on metabolic diseases, oncology, and viral-induced ARDS, with operations in Florida and internationally. It markets FC2, a female condom for dual protection against pregnancy and sexually transmitted infections. Veru develops enobosarm, a selective androgen receptor modulator for fat loss and muscle preservation in sarcopenic obesity and overweight elderly, and sabizabulin for high-risk viral lung disease. Formerly The Female Health Company, renamed in 2017. Based in Miami, Florida.
Company score
- Sentiment
- -0.06
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.09
- Governance
- -0.21
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.04
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!